Show simple item record

dc.contributor.authorMaes, T
dc.contributor.authorMascaró, C
dc.contributor.authorOrtega, A
dc.contributor.authorLunardi, S
dc.contributor.authorCiceri, F
dc.contributor.authorSomervaille, Tim C P
dc.contributor.authorBuesa, C
dc.date.accessioned2015-07-23T15:45:59Zen
dc.date.available2015-07-23T15:45:59Zen
dc.date.issued2015-06en
dc.identifier.citationKDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. 2015, 7 (4):609-26 Epigenomicsen
dc.identifier.issn1750-192Xen
dc.identifier.pmid26111032en
dc.identifier.doi10.2217/epi.15.9en
dc.identifier.urihttp://hdl.handle.net/10541/560945en
dc.description.abstractHistone methylation and demethylation are important processes associated with the regulation of gene transcription, and alterations in histone methylation status have been linked to a large number of human diseases. Initially thought to be an irreversible process, histone methylation is now known to be reversed by two families of proteins containing over 30 members that act to remove methyl groups from specific lysine residues present in the tails of histone H3 and histone H4. A rapidly growing number of reports have implicated the FAD-dependent lysine specific demethylase (KDM1) family in cancer, and several small-molecule inhibitors are in development for the treatment of cancer. An additional role has emerged for KDM1 in brain function, offering additional opportunities for the development of novel therapeutic strategies in neurodegenerative disease. A decade after the identification of KDM1A as a histone demethylase, the first selective inhibitors have now reached the clinic.
dc.language.isoenen
dc.rightsArchived with thanks to Epigenomicsen
dc.titleKDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease.en
dc.typeArticleen
dc.contributor.departmentOryzon Genomics S.A., Carrer Sant Ferran 74, 08940 Cornella de Llobregat, Barcelona,en
dc.identifier.journalEpigenomicsen
html.description.abstractHistone methylation and demethylation are important processes associated with the regulation of gene transcription, and alterations in histone methylation status have been linked to a large number of human diseases. Initially thought to be an irreversible process, histone methylation is now known to be reversed by two families of proteins containing over 30 members that act to remove methyl groups from specific lysine residues present in the tails of histone H3 and histone H4. A rapidly growing number of reports have implicated the FAD-dependent lysine specific demethylase (KDM1) family in cancer, and several small-molecule inhibitors are in development for the treatment of cancer. An additional role has emerged for KDM1 in brain function, offering additional opportunities for the development of novel therapeutic strategies in neurodegenerative disease. A decade after the identification of KDM1A as a histone demethylase, the first selective inhibitors have now reached the clinic.


This item appears in the following Collection(s)

Show simple item record